GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) » Definitions » Tax Expense

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Tax Expense : HK$104 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is SciClone Pharmaceuticals (Holdings) Tax Expense?

SciClone Pharmaceuticals (Holdings)'s tax expense for the months ended in Dec. 2023 was HK$30 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2023 was HK$104 Mil.


SciClone Pharmaceuticals (Holdings) Tax Expense Historical Data

The historical data trend for SciClone Pharmaceuticals (Holdings)'s Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals (Holdings) Tax Expense Chart

SciClone Pharmaceuticals (Holdings) Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
Get a 7-Day Free Trial 51.82 74.82 125.52 94.61 104.45

SciClone Pharmaceuticals (Holdings) Semi-Annual Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 56.22 54.22 42.96 74.44 30.01

SciClone Pharmaceuticals (Holdings) Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$104 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SciClone Pharmaceuticals (Holdings)  (HKSE:06600) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


SciClone Pharmaceuticals (Holdings) Tax Expense Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals (Holdings)'s Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


SciClone Pharmaceuticals (Holdings) (HKSE:06600) Business Description

Traded in Other Exchanges
N/A
Address
381 Middle Huaihai Road, 22nd Floor, Central Plaza, Shanghai, CHN
SciClone Pharmaceuticals (Holdings) Ltd is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. It generated revenue primarily from the sale of Zadaxin to Sinopharm.
Executives
Ubs Group Ag 2201 Interest of corporation controlled by you
Zhao Hong 2101 Beneficial owner
Gl Capital Management Gp Limited
Meng Liang 2201 Interest of corporation controlled by you
Ascendent Silver (cayman) Limited 2501 Other
Ascendent Capital Partners Ii Gp Limited 2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, Gp, L.p. 2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, L.p. 2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd.
Gl China Opportunities Carry Gp Limited
Ocean Falcon Limited 2101 Beneficial owner
Central Huijin Investment Ltd. 2201 Interest of corporation controlled by you
Bank Of China Limited 2201 Interest of corporation controlled by you
Bank Of China Group Investment Limited 2201 Interest of corporation controlled by you
Gl Capital Management Gp Ii B.c I. Ltd

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Headlines

No Headlines